Article
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
The Journal of infectious diseases - 1 Aug 1997
Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T, Boucher C A
Abstract excerpt
Exposure of human immunodeficiency virus to the nucleoside analogue lamivudine (3TC) rapidly selects for resistant variants with a valine at codon 184 (M184V) in the catalytic site of reverse transcriptase. In vitro, 184V demonstrated increased enzyme fidelity and suppressed zidovudine resistance...
Topics
- Amino Acid Sequence
- Anti-HIV Agents
- CD4 Lymphocyte Count
- DNA Mutational Analysis
- DNA, Viral
- Drug Resistance, Microbial
- Drug Resistance, Multiple
- Drug Therapy, Combination
- HIV Infections
- HIV Reverse Transcriptase
- HIV-1
- Humans
- Lamivudine
- Molecular Sequence Data